42
ANZUP ANNUAL REPORT 2017
PUBLICATIONS AND PRESENTATIONS 2016 - 2017
Presentations:
Chambers SK, Occhipinti S, Foley E, Clutton S, Legg M, Berry M, Stockler MR, Frydenberg M, Gardiner RA, Lepore SJ, Davis ID, Smith DP. Mindfulness-based cognitive therapy in advanced prostate cancer: A randomized controlled trial. Journal of Clinical Oncology 2017; 35(3): 291-297.
Oral Presentations
Chambers SK, Foley E, Clutton S, McDowall R, Occhipinti S, Berry M, Stockler MR, Lepore SJ, Frydenberg M, Gardiner RA, Davis ID, Smith DP. The role of mindfulness in distress and quality of life for men with advanced prostate cancer. Quality of Life Research 2016; 25(12): 3027–3035. Lawrence N, Martin A, Toner G, Stockler M, Buizen L, Thomson D, Gebski V, Friedlander M, Yeung A, Wong N, Gurney H, Rosenthal M, Singhal N, Kichenadasse G, Wong S, Lewis C, Vasey P, Grimison P. Long-term outcomes of accelerated BEP (bleomycin, etoposide, cisplatin) for advanced germ cell tumours: updated analysis of an Australian multicentre phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group [letter]. Annals of Oncology 2016; 27(12): 2302–2303. McCombie S, Chang D, Sengupta S, Stockler M, Davis I, Hayne D. Moving toward an evidence and consensus based multicentre enhanced recovery pathway for radical cystectomy: results of an ANZUP survey. BJU International 2016; 117: 98–99. Roncolato FT, Chatfield M, Houghton B, Toner G, Stockler M, Thomson D, Friedlander M, Gurney H, Rosenthal M, Grimison P. The effect of pulmonary function testing on bleomycin dosing in germ cell tumours. Internal Medicine Journal 2016; 46(8): 893–898. Smith AB, Butow P, Olver I, Luckett T, Grimison P, Toner GC, Stockler MR, Hovey E, Stubbs J, Turner S, Hruby G, Gurney H, Alam M, Cox K, King MT. The prevalence, severity, and correlates of psychological distress and impaired healthrelated quality of life following treatment for testicular cancer: a survivorship study. Journal of Cancer Survivorship 2016; 10(2): 223–233.
Lawrence, N. Long-term outcomes of accelerated BEP (bleomycin, etoposide, cisplatin) for advanced germ cell tumors: updated analysis of an Australian multicenter phase II trial. Oral presentation in session: Best of the Best Research in 2016, Medical Oncology Group of Australia Annual Scientific Meeting 2016, August 3-5, Gold Coast, Australia. Lawrence, N. Long-term outcomes of accelerated BEP (bleomycin, etoposide, cisplatin) for advanced germ cell tumors: updated analysis of an Australian multicenter phase II trial. ANZUP Annual Scientific Meeting 2016, July 10-12, Brisbane, Australia.
Poster Presentations Davis ID, Stockler M, Martin A, Hague W, Coskinas X, Yip S, Dazo C, Long A, Lawrence N, Chan H, McDermott R,Chowdhury S, Marchesin V, Deignan O, Parulekar W, Montenegro Suris A, Sweeney C. Randomised phase 3 trial of enzalutamide in first line androgen deprivation therapy for metastatic prostate cancer: the ANZUP ENZAMET Trial (ANZUP 1304). Poster presentation at American Society of Clinical Oncology (ASCO) 2016: June 3 -7, Chicago, United States. J Clin Oncol 34, 2016 (suppl; abstr TPS5090) Howard Chan, Felicia Roncolato, Anne Long, Farshad Foroudi, David Goldstein, Shankar Siva, Ian Davis. Current clinician practices in utilizing radiotherapy and molecularly targeted therapies in treating patients with metastatic renal cell carcinoma: an ANZUP survey. Poster presentation at ANZUP Annual Scientific Meeting 2016: July 2016. Asia Pacific Journal of Clinical Oncology 12 (S3), 2016: 44-51 Williams S, Davis ID, Sweeney C, Stockler M, Martin A, Hague W, Coskinas X, Long A, Yip S, Tu E, Chan H, Lawrence N, McDermott R, Hughes S, Marchesin V, Deignan O, Nguyen P. Randomised phase 3 trial of enzalutamide in androgen deprivation therapy with radiation therapy for high risk, clinically localised, prostate cancer: ENZARAD (ANZUP 1303). Poster presentation at American Society of Clinical Oncology (ASCO) 2016: June 3-7, Chicago, United States. J Clin Oncol 34, 2016 (suppl; abstr TPS5086)
